Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease

被引：161

作者：

De Taeye, B ^{[1
]}

Smith, LH ^{[1
]}

Vaughan, DE ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37232 USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2005年 / 5卷 / 02期

关键词：

D O I：

10.1016/j.coph.2005.01.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A classical perspective of cardiovascular risk does not adequately account for all of the cardiovascular events associated with obesity and diabetes. The combination of hypertriglyceridemia, glucose intolerance and inflammation is linked with increased production of the primary inhibitor of endogenous thrombolysis, plasminogen activator inhibitor-1 (PAW). Recent data suggest that PAW contributes directly to the complications of obesity, including type 2 diabetes, coronary arterial thrombi, and may even influence the accumulation of visceral fat. Therefore, direct inhibition of PAI-1 might not only provide a new therapeutic strategy for reducing cardiovascular risk, but may also have beneficial effects on obesity and insulin resistance.

引用

页码：149 / 154

页数：6

共 35 条

[1] Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity [J].

Alessi, MC ;

Bastelica, D ;

Morange, P ;

Berthet, B ;

Leduc, I ;

Verdier, M ;

Geel, O ;

Juhan-Vague, I .

DIABETES, 2000, 49 (08) :1374-1380

[2] DIURNAL-VARIATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RAPID INHIBITOR (PAI-1) [J].

ANGLETON, P ;

CHANDLER, WL ;

SCHMER, G .

CIRCULATION, 1989, 79 (01) :101-106

[3]

Bastelica D, 2002, THROMB HAEMOSTASIS, V88, P481

[4] Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo [J].

Brown, NJ ;

Nakamura, S ;

Ma, LJ ;

Nakamura, I ;

Donnert, E ;

Freeman, M ;

Vaughan, DE ;

Fogo, AB .

KIDNEY INTERNATIONAL, 2000, 58 (03) :1219-1227

[5] Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 [J].

Brown, NJ ;

Agirbasli, MA ;

Williams, GH ;

Litchfield, WR ;

Vaughan, DE .

HYPERTENSION, 1998, 32 (06) :965-971

[6] ACE inhibition versus angiotensin type 1 receptor antagonism - Differential effects on PAM over time [J].

Brown, NJ ;

Kumar, S ;

Painter, CA ;

Vaughan, DE .

HYPERTENSION, 2002, 40 (06) :859-865

[7] Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells [J].

Chen, YQ ;

Su, M ;

Walia, RR ;

Hao, Q ;

Covington, JW ;

Vaughan, DE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8225-8231

[8] Cardiovascular disease risk factors predict the development of type 2 diabetes - The Insulin Resistance Atherosclerosis Study [J].

D'Agostino, RB ;

Hamman, RF ;

Karter, AJ ;

Mykkanen, L ;

Wagenknecht, LE ;

Haffner, SM .

DIABETES CARE, 2004, 27 (09) :2234-2240

[9] Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation [J].

Du, XL ;

Edelstein, D ;

Rossetti, L ;

Fantus, IG ;

Goldberg, H ;

Ziyadeh, F ;

Wu, J ;

Brownlee, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12222-12226

[10] Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the Pathophysiology of Obesity-Associated Cardiovascular Disease [J].

Eckel, RH ;

Barouch, WW ;

Ershow, AG .

CIRCULATION, 2002, 105 (24) :2923-2928

← 1 2 3 4 →